

Upgrading nirmatrelvir to prevent SARS-CoV-2 Mpro via DeepFrag and free energy calculations

Nguyen Minh Tam,^a Trung Hai Nguyen,^{b,c} Minh Quan Pham,^{d,e} Nam Dao Hong,^f Nguyen Thanh Tung,^{e,g*} Van V. Vu,^h Duong Tuan Quang,^{i,*} and Son Tung Ngo^{b,c,*}

^a*Faculty of Basic Sciences, University of Phan Thiet, Phan Thiet City, Binh Thuan, Vietnam*

^b*Laboratory of Biophysics, Institute for Advanced Study in Technology, Ton Duc Thang University, Ho Chi Minh City, Vietnam*

^c*Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, Vietnam*

^d*Institute of Natural Products Chemistry, Vietnam Academy of Science and Technology, Hanoi, Vietnam*

^e*Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam*

^f*University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam*

^g*Institute of Materials Science, Vietnam Academy of Science and Technology, Hanoi, Vietnam*

^h*NTT Hi-Tech Institute, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam*

ⁱ*Department of Chemistry, Hue University, Thua Thien Hue Province, Hue City, Vietnam*

*Corresponding email: tungnt@ims.vast.ac.vn, dtquang@hueuni.edu.vn and ngosontung@tdtu.edu.vn

Table S1. FPL results of the modified compounds versus PF-07321332 (nirmatrelvir).

Source	N ⁰	Code	F_{Max}	W	$\Delta G_{\text{FPL}}^{\text{Pre a}}$
		PF-07321332	788.3 ± 38.1	103.7 ± 3.6	-11.32
PF-07321332	1	PF_9b	871.1 ± 43.7	122.1 ± 5.0	-12.35
	2	PF_9a	896.9 ± 55.5	119.8 ± 8.2	-12.22
	3	PF_3	890.7 ± 48.4	116.0 ± 4.3	-12.01
	4	PF_35	776.6 ± 61.3	115.4 ± 8.0	-11.97
	5	PF_12	759.7 ± 15.5	107.3 ± 3.0	-11.52
	6	PF_33	779.0 ± 56.3	104.5 ± 5.8	-11.37
	7	PF_34	787.6 ± 55.8	103.7 ± 6.8	-11.32
	8	PF_2	763.7 ± 69.0	97.5 ± 4.8	-10.97
	9	PF_14	689.8 ± 26.6	94.3 ± 4.7	-10.79

Table S2. FPL results of the modified compounds.

Source	N ⁰	Code	F_{Max}	W	$\Delta G_{\text{FPL}}^{\text{Pre a}}$
PF_9b	1	PF_9b_3	730.9 ± 26.1	113.6 ± 3.4	-11.87
	2	PF_9b_13	788.2 ± 15.7	105.1 ± 1.9	-11.40
PF_9a	1	PF_9a_33	882.6 ± 56.9	130.1 ± 7.3	-12.80
	2	PF_9a_11	849.2 ± 18.2	117.3 ± 4.2	-12.08
	3	PF_9a_32	781.5 ± 33.0	113.5 ± 5.3	-11.87
	4	PF_9a_2	803.9 ± 58.9	112.4 ± 4.0	-11.81
	5	PF_9a_13	669.9 ± 21.5	92.0 ± 3.2	-10.67
PF_3	1	PF_3_4	827.5 ± 35.0	116.3 ± 2.7	-12.03
	2	PF_3_34	852.9 ± 35.1	114.9 ± 3.4	-11.95
	3	PF_3_2	764.6 ± 56.8	104.5 ± 5.0	-11.36
	4	PF_3_13	713.8 ± 30.2	98.30 ± 4.7	-11.02
PF_35	1	PF_35_14	627.1 ± 29.8	92.0 ± 3.8	-10.66
PF_12	1	PF_12_33	869.2 ± 6.6	121.9 ± 1.6	-12.34
	2	PF_12_9	877.5 ± 42.9	116.5 ± 5.0	-12.04
	3	PF_12_3	836.7 ± 42.5	114.6 ± 6.4	-11.93
	4	PF_12_32	833.3 ± 28.6	113.2 ± 4.2	-11.85
	5	PF_12_34	842.0 ± 44.8	112.0 ± 3.5	-11.79
	6	PF_12_13	654.9 ± 22.2	88.4 ± 2.3	-10.46

Table S3. FPL results of the modified compounds.


Source	N ⁰	Code	F_{Max}	W	$\Delta G_{\text{FPL}}^{\text{Pre a}}$
PF_9a_33	1	PF_9a_33_13	828.4 ± 14.4	121.0 ± 2.6	-12.29
	2	PF_9a_33_2	787.7 ± 47.7	107.3 ± 6.2	-11.52
	3	PF_9a_33_3	806.5 ± 10.4	101.3 ± 5.1	-11.18
	4	PF_9a_33_32	689.0 ± 36.5	95.3 ± 6.0	-10.85
PF_3_4	1	PF_3_4_62	1032.2 ± 33.5	146.5 ± 5.2	-13.71
	2	PF_3_4_32	978.9 ± 57.6	144.5 ± 4.1	-13.60
	3	PF_3_4_7	957.6 ± 44.0	131.2 ± 3.0	-12.86
	4	PF_3_4_33	922.9 ± 28.1	128.5 ± 3.4	-12.70
	5	PF_3_4_31	908.5 ± 30.7	124.5 ± 4.6	-12.48
	6	PF_3_4_12	811.6 ± 5.6	113.6 ± 2.0	-11.87
	7	PF_3_4_10	717.1 ± 35.8	101.8 ± 2.1	-11.21
PF_12_33	1	PF_12_33_3	882.7 ± 12.2	125.4 ± 5.5	-12.53
	2	PF_12_33_9	839.7 ± 68.3	118.0 ± 9.6	-12.12
	3	PF_12_33_32	802.0 ± 47.3	115.2 ± 3.0	-11.96
	4	PF_12_33_33	816.6 ± 41.5	106.3 ± 5.0	-11.47
	5	PF_12_33_5	706.9 ± 49.0	105.7 ± 1.7	-11.43
PF_12_9	1	PF_12_9_31	940.2 ± 15.4	133.5 ± 2.2	-12.99
	2	PF_12_9_3	906.7 ± 34.0	125.8 ± 4.6	-12.55
	3	PF_12_9_5	885.3 ± 24.0	116.8 ± 5.2	-12.06
	4	PF_12_9_32	726.0 ± 44.7	107.3 ± 4.1	-11.52
	5	PF_12_9_33	760.3 ± 8.8	101.2 ± 2.5	-11.18
	6	PF_12_9_12	683.1 ± 8.6	97.5 ± 1.4	-10.97
	7	PF_12_9_2	721.8 ± 25.9	90.5 ± 4.0	-10.58


Table S4. FPL results of the modified compounds.


Source	N ⁰	Code	F _{Max}	W	ΔG _{FPL} ^{Pre a}
PF_3_4_62	1	PF_3_4_62_33	927.7 ± 28.0	122.6 ± 4.2	-12.38
	2	PF_3_4_62_12	785.7 ± 32.5	101.8 ± 6.3	-11.21
	3	PF_3_4_62_32	731.7 ± 60.3	100.4 ± 5.7	-11.13
	4	PF_3_4_62_10	661.4 ± 31.4	86.7 ± 4.1	-10.37
PF_3_4_32	1	PF_3_4_32_32	911.3 ± 24.8	126.3 ± 3.8	-12.58
	2	PF_3_4_32_10	837.0 ± 60.4	121.1 ± 7.1	-12.30
PF_3_4_7	1	PF_3_4_7_30	792.3 ± 66.8	119.4 ± 8.1	-12.20
	2	PF_3_4_7_9	792.7 ± 26.7	103.5 ± 6.9	-11.31
	3	PF_3_4_7_31	640.4 ± 38.9	89.9 ± 2.5	-10.55
	4	PF_3_4_7_32	660.3 ± 28.9	89.6 ± 5.8	-10.53
	5	PF_3_4_7_11	611.1 ± 43.3	76.1 ± 4.3	-9.77
PF_3_4_33	1	PF_3_4_33_32	927.2 ± 39.3	142.2 ± 6.2	-13.47
	2	PF_3_4_33_31	908.0 ± 63.5	134.7 ± 8.1	-13.05
	3	PF_3_4_33_12	676.8 ± 22.7	98.3 ± 4.1	-11.01
PF_3_4_31	1	PF_3_4_31_32	863.1 ± 45.1	123.3 ± 6.1	-12.42
	2	PF_3_4_31_10	795.4 ± 49.9	109.5 ± 4.1	-11.65
	3	PF_3_4_31_12	729.7 ± 51.4	105.4 ± 5.4	-11.41
PF_12_33_3	1	PF_12_33_3_32	804.3 ± 28.3	111.8 ± 4.0	-11.77
	2	PF_12_33_3_31	727.1 ± 53.1	100.2 ± 5.0	-11.12
	3	PF_12_33_3_8	691.5 ± 32.2	94.9 ± 4.9	-10.83
	4	PF_12_33_3_2	729.6 ± 21.6	89.9 ± 4.9	-10.55
	5	PF_12_33_3_4	656.4 ± 36.4	87.6 ± 4.6	-10.42
PF_12_9_31	1	PF_12_9_31_32	836.6 ± 28.1	126.8 ± 3.9	-12.61
	2	PF_12_9_31_3	829.9 ± 43.2	112.7 ± 5.9	-11.82
	3	PF_12_9_31_2	705.3 ± 29.1	89.6 ± 3.6	-10.53
PF_12_9_3	1	PF_12_9_3_31	690.2 ± 44.7	97.7 ± 4.0	-10.98
	2	PF_12_9_3_30	587.0 ± 43.2	87.6 ± 3.9	-10.42
	3	PF_12_9_3_32	569.0 ± 35.0	73.7 ± 4.1	-9.64
	4	PF_12_9_3_11	532.9 ± 40.3	72.9 ± 3.7	-9.59


Table S5. FPL results of the modified compounds.


Source	N ⁰	Code	F_{Max}	W	$\Delta G_{\text{FPL}}^{\text{Pre}^a}$
PF_3_4_33_32	1	PF_3_4_33_32_10	658.0 ± 37.5	95.3 ± 5.5	-10.85
	2	PF_3_4_33_32_60	737.6 ± 19.2	95.2 ± 2.52	-10.84
PF_3_4_31	1	PF_3_4_33_31_60	813.8 ± 12.4	105.0 ± 1.4	-11.39
	2	PF_3_4_33_31_10	646.1 ± 31.5	95.9 ± 3.4	-10.88


Table S6. The profile of pulling work over the ligand displacement. The calculations were repeated 4 times each system.






























Table S7. The 2D interaction diagram between SARS-CoV-2 Mpro + ligand.

N ^o	Name	Initial Structure ^a	MD-refined structure ^b
1	PF-07321332		
2	PF_9b		
3	PF_9a		














20	PF_3_2		
21	PF_3_13		
22	PF_35_14		
23	PF_12_33		




















52	PF_3_4_62_33		
53	PF_3_4_62_12		
54	PF_3_4_62_32		
55	PF_3_4_62_10		







64	PF_3_4_33_31		
65	PF_3_4_33_12		
66	PF_3_4_31_32		
67	PF_3_4_31_10		

68	PF_3_4_31_12		
69	PF_12_33_3_32		
70	PF_12_33_3_31		
71	PF_12_33_3_8		



76	PF_12_9_31_2		
77	PF_12_9_3_31		
78	PF_12_9_3_30		
79	PF_12_9_3_32		

84 PF_3_4_33_31_10



^aThe initial conformation of the complex, which was provided by DeepFrag application. ^bThe MD-refined structure of the complex.

Table S8. Toxicity prediction via PreADMET.

N ^o	Compound	Carcino _{Mouse}	Ames _{test}	TA100 _{10RLI}	TA100 _{NA}	TA1535 _{10RLI}	TA1535 _{NA}
1	PF_3_4_62	negative	non-mutagen	negative	negative	negative	negative
2	PF_3_4_32	negative	non-mutagen	negative	negative	negative	negative
3	PF_3_4_33_32	negative	non-mutagen	negative	negative	negative	negative
4	PF_3_4_33_31	negative	non-mutagen	negative	negative	negative	negative
5	PF_12_9_31	negative	non-mutagen	negative	negative	negative	negative
6	PF_3_4_7	negative	non-mutagen	negative	negative	negative	negative
7	PF_9a_33	negative	non-mutagen	negative	negative	negative	negative
8	PF_3_4_33	negative	non-mutagen	negative	negative	negative	negative
9	PF_12_9_31_32	negative	non-mutagen	negative	negative	negative	negative
10	PF_3_4_32_32	negative	non-mutagen	negative	negative	negative	negative
11	PF_12_9_3	negative	non-mutagen	negative	negative	negative	negative
12	PF_12_33_3	negative	non-mutagen	negative	negative	negative	negative
13	PF_3_4_31	negative	non-mutagen	negative	negative	negative	negative
14	PF_3_4_31_32	negative	non-mutagen	negative	negative	negative	negative
15	PF-07321332	positive	non-mutagen	positive	positive	positive	positive